Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir [5]

AIDS

Volumn 20, Issue 7, 2006, Pages 1085-1087

  Martin, Troy M ^a   Morse, Gene D ^b   Kurpewski, Jaclynn ^a   Difrancesco, Robin ^b   Caliendo, Angela M ^c   Flanigan, Timothy P ^a   Tashima, Karen T ^a  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PYRIMIDINONES; RITONAVIR;

EID: 33646343982     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1175/JPO2881.1     Document Type: Letter

References (6)

1. Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 2002; 16:595-609.
2. Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19:949-992.
3. Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 2003; 25:340-346.
4. Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF, and semen. J Antimicrob Chemother 2004; 54:498-502.
5. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
6. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experience, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005; 79:3329-3338.